Disease · EFO_1001769

carcinoid heart disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. carcinoid heart disease. Diseases, record EFO_1001769. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001769

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: carcinoid heart disease; Open Targets
Open Targets ID: EFO_1001769; Open Targets
MeSH: D002275; MeSH
Highest stage of its drugs: Phase 3, for 1 of its 2 drugs, from ClinicalTrials.gov; Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TELOTRISTAT ETHYL	CHEMBL2105695	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LUTETIUM OXODOTREOTIDE LU-177	CHEMBL4297545	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets7

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SSTR1	Somatostatin receptor	1	Somatostatin receptor binding agent	Phase 2	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR2	Somatostatin receptor	1	Somatostatin receptor binding agent	Phase 2	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR3	Somatostatin receptor	1	Somatostatin receptor binding agent	Phase 2	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR4	Somatostatin receptor	1	Somatostatin receptor binding agent	Phase 2	https://conductscience.org/library/genes/6754	Drugs and targets
SSTR5	Somatostatin receptor	1	Somatostatin receptor binding agent	Phase 2	https://conductscience.org/library/genes/6755	Drugs and targets
TPH1	Tryptophan 5-hydroxylase	1	Tryptophan 5-hydroxylase inhibitor	Phase 3	https://conductscience.org/library/genes/7166	Drugs and targets
TPH2	Tryptophan 5-hydroxylase	1	Tryptophan 5-hydroxylase inhibitor	Phase 3	https://conductscience.org/library/genes/121278	Drugs and targets

Trials2

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04810091	Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor	Phase 3	79	2026-02-05	Locally Advanced Neuroendocrine Neoplasm, Metastatic Neuroendocrine Neoplasm	TELOTRISTAT ETHYL	Its record names the disease	ClinicalTrials.gov
NCT04039516	Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy	Phase 2	20		Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor	LUTETIUM OXODOTREOTIDE LU-177	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Placebo + SSA vs Xermelo + SSA: deaths from any cause	1 of 35	0 of 32	67	NCT04810091	Trial comparisons
Placebo + SSA vs Xermelo + SSA: serious adverse events	3 of 35	4 of 32	67	NCT04810091	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1001769

GET https://conductscience.org/api/diseases/v1/EFO_1001769/drugs

API reference For AI assistants